Investigation of adverse effects of oral voriconazole in the treatment of fungal infection using The FDA Adverse Event Reporting System (FAERS)
| bracu.degree.level | Undergraduate | |
| bracu.type.group | Student Works | |
| datacite.rights | Open Access | |
| dc.contributor.advisor | Talukder, Mesbah | |
| dc.contributor.author | Onanna, Kazi | |
| dc.contributor.department | School of Pharmacy | |
| dc.date.accessioned | 2024-05-29T06:44:19Z | |
| dc.date.available | 2024-05-29T06:44:19Z | |
| dc.date.copyright | 2023 | |
| dc.date.issued | 2023-07 | |
| dc.description | Cataloged from PDF version of thesis. | |
| dc.description | Includes bibliographical references (pages 16-18). | |
| dc.description | This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. | en_US |
| dc.description.abstract | This investigation examines pharmacovigilance databases to find the most common adverse effects associated with voriconazole. I performed a statistical analysis of voriconazole adverse events using data from the FDA's Adverse Event Reporting System (FAERS). Each adverse event was assigned a frequency and reported odds ratio (ROR). A total of 2511 reports were produced by the FAERS database. While voriconazole remains an important medicine for fungal treatment, the adverse reactions associated with voriconazole should be considered. The Major five adverse effect of voriconazole was highlighted in this study based on the highest number of signals received. | en_US |
| dc.description.degree | Bachelor of Pharmacy | |
| dc.description.statementofresponsibility | Kazi Onanna | |
| dc.format.extent | 30 pages | |
| dc.identifier.other | ID 19346063 | |
| dc.identifier.uri | http://hdl.handle.net/10361/22989 | |
| dc.language.iso | en | en_US |
| dc.publisher | BRAC University | en_US |
| dc.rights | Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
| dc.subject | Food and Drug Administration Adverse Event Reporting System (FAERS) | en_US |
| dc.subject | Reported odds ratios (ROR) | en_US |
| dc.subject | Fungal treatment | en_US |
| dc.subject | Adverse reactions | en_US |
| dc.subject | Pharmacovigilance | en_US |
| dc.subject.lcsh | Fungal Infection--Treatment | |
| dc.title | Investigation of adverse effects of oral voriconazole in the treatment of fungal infection using The FDA Adverse Event Reporting System (FAERS) | en_US |
| dc.type | Thesis | en_US |